insulin degludec (Geropharm)

GP40311 is a biosimilar of insulin degludec, a long-acting basal insulin analogue developed by Geropharm. It is designed to provide glycemic control in patients with diabetes mellitus. Insulin degludec is characterized by its unique mechanism of forming multi-hexamers upon subcutaneous injection, which results in a slow and continuous release of insulin into the circulation. This provides a duration of action exceeding 42 hours and a stable, flat glucose-lowering effect with low day-to-day variability. As a biosimilar, GP40311 is intended to offer a more affordable alternative to the reference product, Tresiba, particularly in the Russian and CIS markets.

Brand names

Degludec Geropharm

Other names

GP40311GP-40311GP 40311